HRP20030833B1 - Liquid pharmaceutical composition - Google Patents

Liquid pharmaceutical composition

Info

Publication number
HRP20030833B1
HRP20030833B1 HR20030833A HRP20030833A HRP20030833B1 HR P20030833 B1 HRP20030833 B1 HR P20030833B1 HR 20030833 A HR20030833 A HR 20030833A HR P20030833 A HRP20030833 A HR P20030833A HR P20030833 B1 HRP20030833 B1 HR P20030833B1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
composition
polyhydric alcohols
volume
Prior art date
Application number
HR20030833A
Other languages
English (en)
Croatian (hr)
Inventor
Mahesh Kulkarni Neema
Schneider Michael
Bernard Silbering Steven
Richard Meyer-Wonnay Hans
Sanii-Yahyai Nahid
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030833(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of HRP20030833A2 publication Critical patent/HRP20030833A2/hr
Publication of HRP20030833B1 publication Critical patent/HRP20030833B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20030833A 2001-05-25 2002-04-29 Liquid pharmaceutical composition HRP20030833B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Publications (2)

Publication Number Publication Date
HRP20030833A2 HRP20030833A2 (en) 2004-08-31
HRP20030833B1 true HRP20030833B1 (en) 2007-04-30

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030833A HRP20030833B1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Country Status (43)

Country Link
US (2) US20020198261A1 (pl)
EP (1) EP1395242B1 (pl)
JP (1) JP2004534764A (pl)
KR (1) KR100582963B1 (pl)
CN (1) CN100346779C (pl)
AP (1) AP1815A (pl)
AR (1) AR033922A1 (pl)
AT (1) ATE334656T1 (pl)
AU (1) AU2002258026B2 (pl)
BG (1) BG108376A (pl)
BR (1) BR0209973A (pl)
CA (1) CA2446574C (pl)
CR (1) CR7150A (pl)
CY (1) CY1105147T1 (pl)
CZ (1) CZ299755B6 (pl)
DE (1) DE60213592T2 (pl)
DK (1) DK1395242T3 (pl)
DO (1) DOP2002000403A (pl)
EA (1) EA008087B1 (pl)
EE (1) EE200300587A (pl)
EG (1) EG24078A (pl)
ES (1) ES2265040T3 (pl)
GE (1) GEP20053620B (pl)
HR (1) HRP20030833B1 (pl)
HU (1) HUP0401366A2 (pl)
IL (1) IL158359A0 (pl)
IS (1) IS2428B (pl)
MA (1) MA27026A1 (pl)
MX (1) MXPA03009392A (pl)
MY (1) MY128615A (pl)
NO (1) NO20035200L (pl)
NZ (1) NZ529173A (pl)
OA (1) OA12604A (pl)
PA (1) PA8545901A1 (pl)
PE (1) PE20030087A1 (pl)
PL (1) PL366384A1 (pl)
PT (1) PT1395242E (pl)
RS (1) RS87203A (pl)
SI (1) SI1395242T1 (pl)
SK (1) SK286227B6 (pl)
SV (1) SV2003001053A (pl)
WO (1) WO2002094220A1 (pl)
ZA (1) ZA200308393B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2494811A1 (en) * 2002-08-15 2004-02-26 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
MXPA06002789A (es) * 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
AU2004280240B2 (en) * 2003-10-08 2010-04-22 SpecGx LLC Methylphenidate solution and associated methods of administration and production
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
US20080112893A1 (en) * 2004-10-14 2008-05-15 Arai Jun-Ichiro Atmosphere Modifying Method and Spray Agent and Spray Device Used in the Same
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
US11738020B2 (en) 2018-08-18 2023-08-29 Ftf Pharma Private Limited Stable liquid vigabatrin pharmaceutical composition for oral dosage
EP3836898A2 (en) * 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
EP3836899A2 (en) 2018-08-18 2021-06-23 FTF Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
CA3131336A1 (en) * 2019-03-26 2020-10-01 Mirja Huhtinen Pregabalin formulations and use thereof
WO2022157527A1 (en) 2021-01-22 2022-07-28 Egis Gyógyszergyár Zrt. Topical formulation containing dispersed pregabalin
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
WO2022168968A1 (ja) * 2021-02-05 2022-08-11 学校法人近畿大学 末梢神経障害の予防又は改善剤
EP4395758A4 (en) * 2021-08-31 2025-07-30 Avion Pharmaceuticals Llc STABLE GABAPENTIN POWDER
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
HU228771B1 (en) * 1998-05-15 2013-05-28 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
AP2001002360A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors.

Also Published As

Publication number Publication date
OA12604A (en) 2006-06-08
US20020198261A1 (en) 2002-12-26
NZ529173A (en) 2005-07-29
PA8545901A1 (es) 2003-09-05
AP2003002907A0 (en) 2003-12-31
KR100582963B1 (ko) 2006-05-24
CY1105147T1 (el) 2010-03-03
DE60213592T2 (de) 2007-08-09
EG24078A (en) 2008-05-11
DK1395242T3 (da) 2006-10-30
HRP20030833A2 (en) 2004-08-31
EE200300587A (et) 2004-02-16
CZ20033066A3 (cs) 2004-08-18
DOP2002000403A (es) 2002-11-30
CN100346779C (zh) 2007-11-07
SK14112003A3 (sk) 2004-08-03
JP2004534764A (ja) 2004-11-18
CZ299755B6 (cs) 2008-11-12
HUP0401366A2 (hu) 2004-11-29
CA2446574A1 (en) 2002-11-28
AR033922A1 (es) 2004-01-07
CA2446574C (en) 2008-04-01
CR7150A (es) 2004-02-23
BG108376A (bg) 2005-04-30
PE20030087A1 (es) 2003-02-14
ATE334656T1 (de) 2006-08-15
IS6986A (is) 2003-10-09
SK286227B6 (sk) 2008-05-06
EP1395242B1 (en) 2006-08-02
AP1815A (en) 2008-01-04
US7256216B2 (en) 2007-08-14
US20040072904A1 (en) 2004-04-15
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
HK1062646A1 (zh) 2004-11-19
KR20040003006A (ko) 2004-01-07
WO2002094220A1 (en) 2002-11-28
SV2003001053A (es) 2003-03-18
AU2002258026B2 (en) 2007-08-02
ZA200308393B (en) 2005-04-26
GEP20053620B (en) 2005-09-26
MY128615A (en) 2007-02-28
NO20035200D0 (no) 2003-11-24
ES2265040T3 (es) 2007-02-01
EA008087B1 (ru) 2007-02-27
EP1395242A1 (en) 2004-03-10
PL366384A1 (pl) 2005-01-24
NO20035200L (no) 2003-11-24
IS2428B (is) 2008-10-15
DE60213592D1 (de) 2006-09-14
IL158359A0 (en) 2004-05-12
SI1395242T1 (en) 2006-10-31
CN1509165A (zh) 2004-06-30
MA27026A1 (fr) 2004-12-20
BR0209973A (pt) 2004-04-06
EA200301152A1 (ru) 2004-04-29
RS87203A (sr) 2006-10-27

Similar Documents

Publication Publication Date Title
HRP20030833B1 (en) Liquid pharmaceutical composition
ATE276735T1 (de) Zusammensetzung zur hautdesinfektion
EP1649760A4 (en) COMPOSITION CONTAINING EQUOLPRODUCATING MILKY ACID BACTERIA
EP0732930A4 (en) Compositions that inhibit apoptosis, method of cleaning the compositions and their use
HN2002000154A (es) Azaindoles
ATE409512T1 (de) Verbindungen zur kontrollierten freigabe aktiver molekülen
ATE275562T1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
DK1273299T3 (da) Minoxidilinindeholdende praparater
MY133174A (en) Dipeptide nitriles
UY27329A1 (es) Champues con alcohol de behenilo
CR8107A (es) Fungicida
ES2193874B1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
HRP20070577T4 (hr) Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida
DE602004005890D1 (de) Moschus-geruchsstoffe
DE60311830D1 (de) Wasserlöslicher behälter
DE60132441D1 (de) A als inhibitor der no-synthase und verwendungen
HRP20030576B1 (en) Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof
PL1553162T3 (pl) Toaletowe kostki
TNSN98013A1 (fr) Derives de 5 - aroylnaphtalene a action anti-inflammatoire et analgesique, compositions pharmaceutiques les contenant, et procedes pour les utiliser et les preparer.
ATE342880T1 (de) Aliphatische verbindungen als duftstoffe mit moschuscharakter
CO5590936A2 (es) Compuesto farmaceutico que contiene sfcyr iib o sfcyr iii
WO2002056840A3 (de) Kosmetisches und/oder pharmazeutisches mittel acylierte aminosaüre enthaltend.
DE60105028D1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
GB0319165D0 (en) Improved cleaning composition
PT1250125E (pt) Composicoes farmaceuticas contendo terbinafina

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080402

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20090430